Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Teva Pharmaceutical Industries Limited

Key Points
Sold 300,619 BBWI shares; estimated trade value ~$7.74 million based on quarterly average pricing.
Net position value change was $7.74 million, reflecting both trading activity and price movements.
Represents a 4.98% change in 13F reportable AUM.
Post-trade: 0 shares held, $0 position value.
Exiting a stake previously at 4.2% of AUM.
On February 17, 2026, Bridger Management, LLC disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold all of its Bath & Body Works (NYSE:BBWI) shares in the fourth quarter.
What happened
According to an SEC filing dated February 17, 2026, Bridger Management, LLC sold all 300,619 shares of Bath & Body Works during the fourth quarter. The estimated transaction value was $7.74 million, calculated using the average price for the quarter.
What else to know
Top holdings after the filing:
NYSE:MS: $24.27 million (15.6% of AUM)
NASDAQ:AMZN: $15.30 million (9.8% of AUM)
NYSE:TEVA: $11.47 million (7.4% of AUM)
NYSE:NKE: $11.45 million (7.4% of AUM)
NYSE:ALC: $8.53 million (5.5% of AUM)
As of February 17, 2026, shares were priced at $24.67, down 32.3% over one year, underperforming the S&P 500 by 38.07 percentage points.
Fund downsizing: total 13F AUM shrank by 16% quarter-over-quarter.
Company Overview
Revenue (TTM)
$7.35 billion
Net Income (TTM)
$699.00 million
Dividend Yield
3.24%
Price (as of market close 2/17/26)
$24.67
Company Snapshot
Offers home fragrance, body care, soaps, and sanitizer products under the Bath & Body Works and White Barn brands through retail stores and e-commerce channels.
Generates revenue primarily from direct-to-consumer sales in company-operated stores and online, supplemented by international franchise, license, and wholesale arrangements.
Targets retail consumers in the United States and Canada, with additional reach through international partners.
Bath & Body Works, Inc. is a leading specialty retailer with a focus on personal care and home fragrance products, operating a broad network of company-operated and partner stores.
What this transaction means for investors
Bridger Management has sold out of Bath & Body Works stock at a difficult time for the company.
The fund had held shares of the stock since the second quarter of 2023. Its performance struggled during the time Bridger owned it before the stock price began to crater as the fund sold it.
Historically, the company had stood out in this highly competitive market with brand loyalty, a robust supply chain, and omnichannel retailing.
However, in recent years, sales levels have stagnated amid shifting buying patterns and falling popularity with Gen Z. In Q3, these trends culminated with the company lowering its guidance for the remainder of 2025 and analysts forecasting lower sales in 2026.
Indeed, amid a low valuation, Bath & Body Works stock staged a modest rebound beginning in late 2025. Still, even with a P/E ratio of less than 8, the fund decided to close its position, indicating Bridger did not have a high degree of faith in a rebound for the retail stock.
Should you buy stock in Bath & Body Works right now?
Before you buy stock in Bath & Body Works, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bath & Body Works wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,174,241!*
Now, it’s worth noting Stock Advisor’s total average return is 889% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 24, 2026.
Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Nike. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Bridger Dumps 301,000 Bath & Body Works Shares Worth $7.7 Million

(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749). This investigational therapy is being developed for the treatment of schizophrenia in adults.
Currently, there is no long-acting olanzapine formulation available without an FDA-required Risk Evaluation and Mitigation Strategy (REMS). The REMS program mandates administration in a certified healthcare facility and requires patients to remain under observation for three hours following injection.
The Phase 3 SOLARIS trial evaluated TEV-'749 as a once-monthly subcutaneous injection. Results showed that its efficacy and safety profile was consistent with existing olanzapine formulations, while importantly demonstrating no evidence to support the need for post-injection monitoring.
TEV-'749, developed by Teva Pharmaceuticals and Medincell, represents a potential advancement in schizophrenia treatment. It offers a once-monthly subcutaneous long-acting injectable (LAI) of the second-generation atypical antipsychotic olanzapine. However, it remains investigational and has not yet been approved by any regulatory authority for clinical use.
TEVA closed Friday's regular trading at $34.22 down $0.11 or 0.32%. In after-hours trading, the stock slipped further to $33.90, down $0.32 points or 0.94%.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment

(RTTNews) - The biotech space this week witnessed significant key milestones, including FDA approvals, NDA path-setting meetings, rejections, licensing agreements, and oncology drug acquisitions.
The clinical trial arena achieved positive results in therapeutic areas such as idiopathic nephrotic syndrome, age-related macular degeneration, ulcerative colitis, plaque psoriasis, obesity, autoimmune and inflammatory diseases.
Let us unpack the key developments and milestones of this week.
FDA Approvals & Rejections
NRx Pharmaceuticals, Inc. (NRXP) has completed a Type C guidance meeting with the U.S. FDA related to NRX-100 (preservative-free ketamine). The FDA indicated that existing clinical trial data plus Real-World Evidence from over 65,000 patients could support an NDA under Fast Track Designation, with no additional nonclinical or bridging studies required.
NRx plans to seek a broader indication in treatment-resistant depression with suicidality and will finalize its Real-World Evidence analysis protocol in the coming weeks. The meeting included input from Osmind, Inc., Psychiatry Products, and leadership of FDA's CDER and OSMID.
NRXP closed Thursday's (February 19, 2026) trading at $1.84, up 3.66%.
Kane Biotech Inc. (KNBIF) announced that the U.S. FDA has granted 510(k) clearance for its Revyve Antimicrobial Skin and Wound Cleanser, supporting its use across a broad range of acute and chronic dermal lesions. The clearance reinforces the reyvye platform's ability to target wound bacteria and biofilms, with manufacturing scale-up and technology transfer planned for later in 2026.
The company also expanded its ISO certification under MDSAP to include distribution and wound cleaners, aligning with the FDA's new Quality Management System Regulation. The revyve product line-including the Antimicrobial Wound Gel and Wound Gel Spray- is already FDA-cleared and approved by Health Canada.
KNBIF closed Thursday's trading at $0.02, down 1.69%.
The FDA has approved Johnson & Johnson's (JNJ) simplified monthly dosing schedule for RYBREVANT FASPRO or amivantamab and hyaluronidase-lpuj, allowing patients to transition to monthly dosing as early as week 5. The company noted that when combined with oral LAZCLUZE for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer, the monthly regimen delivers consistent outcomes with the previously approved bi-weekly subcutaneous schedule.
JNJ closed Thursday's trading at $246.91, up 0.78%.
Spruce Biosciences Inc. (SPRB) announced positive feedback from two FDA Type B meetings supporting its planned BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo syndrome type B.
The agency indicated that integrated clinical and natural-history data may support accelerated approval using CSF HS- NRE as a reasonably likely surrogate endpoint and outlined CMC requirements ahead of a targeted fourth-quarter 2026 filing.
SPRB closed Thursday's trading at $52.62, down 1.61%.
Moderna, Inc. (MRNA) announced that the U.S. FDA has agreed to initiate the review of its BLA for mRNA-1010, the company's investigational seasonal influenza vaccine, following a recent Type A meeting. The agency had previously issued a Refusal-to-File letter, but Moderna resubmitted an amended application seeking full approval for adults 50-64 and accelerated approval for adults 65 and older, along with a post-marketing study requirement. The FDA has now accepted the filing and set a PDUFA date of August 5, 2026, with potential U.S. availability for the 2026/2027 flu season. Moderna added that mRNA-1010 is also under review in Europe, Canada, and Australia.
MRNA closed Thursday's trading at $49.70, up 6.65%.
Disc Medicine Receives CRL for Bitopertin in EPP
Disc Medicine, Inc. (IRON) announced receipt of a Complete Response Letter (CRL) from the U.S. FDA for its NDA seeking accelerated approval of Biopertin for erythropoietic protoporphyria (EPP). While the agency acknowledged Biopertin's ability to lower PPIX levels and supported the biomarker's mechanistic rationale, it cited insufficient correlation with sunlight exposure endpoints. Disc plans to submit results from the ongoing Phase 3 APOLLO trial, with topline data expected in Q4 2026, and will request a Type A meeting to discuss next steps toward traditional approval.
IRON closed Thursday's trading at $63.35, down 1.75%.
AbbVie Inc. (ABBV) and Genetech, a member of Roche Holding AG (RHHBY), announced FDA approval of the combination regimen of VENCLEXTA (venetoclax) and Acalabrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL). The approval was supported by results from the Phase III AMPLIFY study, which showed the regimen reduced the risk of disease progression or death by 35% compared with standard chemoimmunotherapy. VENCLEXTA is already approved across CLL, SLL, and AML indications, and the new frontline approval expands its reach as a chemotherapy-free option. The companies jointly commercialize VENCLEXTA in the U.S., with AbbVie marketing the therapy outside the U.S.
ABBV closed Thursday's trading at $224.35, down 1.91%.
Deals
Theriva Biologics, Inc. (TOVX), a clinical-stage company, has entered into an exclusive worldwide license agreement with Rasayana Therapeutics for the development and commercialisation of SYN-020, an oral recombinant intestinal alkaline phosphatase enzyme.
SYN-020 is designed to restore intestinal barrier function and reduce systemic inflammation by targeting gut-organ axis biology.
Under the terms of the deal, Theriva received a $3 million upfront payment and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales.
Rasayana will assume full responsibility and costs for advancing SYN-020 through clinical development and commercialisation.
TOVX closed Thursday's trading at $0.19, up at 2.45%.
Sensei Acquires Faeth Therapeutics
Sensei Biotherapeutics, Inc. (SNSE), a clinical-stage oncology firm, announced it has acquired Faeth Therapeutics Inc., a clinical-stage biotechnology company developing multi-node therapies that target tumour metabolism and signalling.
The deal brings Faeth's lead asset, PIKTOR- an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway- into Sensei's portfolio, expanding its development focus across endometrial and breast cancer.
Concurrently, Sensei announced a concurrent private placement of $200 million, and intend to use the gross proceeds primarily to advance the acquired PIKTOR through key clinical milestones, including topline data from an ongoing Phase 2 trial in second-line advanced endometrial cancer, as well as the initiation of a Phase 1b trial in HR+/HER2- advanced breast cancer, both expected by year-end 2026.
SNSE closed Thursday's trading at $27.22, up 3.70%.
Clinical Trials - Breakthroughs
Eli Lilly and Co. (LLY) announced positive topline results from the TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz and Zepbound compared to Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight.
At 36 weeks, treatment with Taltz and Zepbound met the primary and all key secondary endpoints, delivering superior skin clearance and weight loss versus Taltz monotherapy.
In the study, 27.1% of participants receiving Taltz and Zepbound reached complete skin clearance or PASI 100 and at least 10% weight loss, compared to 5.8% of patients treated with Taltz alone.
In a key secondary endpoint, Taltz plus Zepbound delivered a 40% relative increase over Taltz monotherapy in the proportion of patients who achieved PASI 100, demonstrating that treatment of obesity or overweight with Zepbound reduced the burden of psoriasis.
LLY closed Thursday's trading at $1023.22, up 0.26%
Zealand Pharma A/S (ZEAL) reported positive topline results from its Phase 1a clinical trial of ZP9830, which is a Kv1.3 channel blocker for autoimmune and inflammatory diseases.
The first-in-human single ascending dose (SAD) part of the combined SAD/multiple ascending dose (MAD) Phase 1a trial was conducted in healthy male participants to investigate the effects of single ascending doses of ZP9830 administered subcutaneously across a wide dose range, as well as intravenously at one dose level.
The study met its primary endpoint, demonstrating safety and tolerability in healthy volunteers. Secondary endpoints also confirmed target engagement, supporting further development of the candidate.
In addition, results showed dose-dependent target engagement with no serious adverse events reported.
Zealand Pharma expects Phase 1a multiple ascending dose data and Phase 1b/2a initiation in H2 2026.
ZEAL.CO closed Thursday's trade at $382.80 DKK, down 0.25%.
Novartis AG (NVS, NOVN.SW), a healthcare firm, announced positive results from a phase 3 trial of its oral drug, Remibrutinib, in chronic inducible urticaria.
Remibrutinib is a selective, oral BTK inhibitor that blocks the BTK pathway involved in the release of histamine, a key driver of hives and swelling.
In the phase 3 trial, dubbed RemIND, Remibrutinib achieved significantly higher complete response rates than placebo at Week 12, i.e., the primary endpoint for the study. This key goal was met for the three most prevalent types of chronic inducible urticaria (CIndU), namely symptomatic dermographism, cold urticaria and cholinergic urticaria.
NVS closed Thursday's trading at $163.92, down 0.88%.
Ocular Therapeutix, Inc. (OCUL) reported positive topline results from its pivotal Phase 3 SOL-1 trial that evaluated AXPAXLI against aflibercept in wet age-related macular degeneration (AMD). But the stock plunged over 20% that day as investors were disappointed that the control arm of aflibercept performed better than expected.
The SOL-1 trial compared a single intravitreal dose of AXPAXLI (OTX-TKI), a bioresorbable hydrogel incorporating axitinib, against aflibercept (2 mg).
At Week 36, 74.1% of patients in the AXPAXLI arm-maintained vision, a statistically significant improvement over aflibercept.
AXPAXLI also demonstrated durability at Week 52, with 65.9% of AXPAXLI-treated patients maintaining vision compared to 44.2% in the control arm.
Rescue-free rates remained high, with nearly two-thirds of patients avoiding supplemental injections through Week 52.
Safety findings were favourable, with no treatment-related ocular or systemic serious adverse events observed
This marks the first successful demonstration of superiority over an approved anti-VEGF therapy in an FDA-aligned study.
OCUL closed Thursday's trading at $7.03, up 2.18%
Rallybio (RLYB), a clinical-stage biotechnology company, announced positive results from its phase 1 clinical trial evaluating RLYB116 in immune platelet transfusion refractoriness and refractory antiphospholipid syndrome.
The Phase 1 clinical trial is a confirmatory pharmacokinetic/pharmacodynamic trial evaluating RLYB116.
RLYB116 is Rallybio's lead once-weekly, small volume, subcutaneously injected C5 inhibitor, in development for patients with complement-mediated diseases with its initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS).
The study evaluated a 4-week treatment duration that included two cohorts of eight participants each, randomized 3-to-1 to receive either RLYB116 or placebo once weekly. Cohort 1 evaluated dosing of 150 mg and Cohort 2 evaluated dosing of 300 mg.
The study demonstrated that 300 mg once-a-week dose RLYB116 achieved complete and sustained inhibition of terminal complement.
Rallybio plans to initiate the RLYB116 phase 2 clinical trial for immune platelet transfusion refractoriness in the second half of 2026, with potential for topline data in 2027.
RLYB closed Thursday's trading at $4.75, up at 5.20%.
Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) highlighted new Phase 2b maintenance data for Duvakitug in patients with ulcerative colitis (UC) and Crohn's disease (CD).
The RELIEVE UCCD long-term extension (LTE) study followed patients who had responded to Duvakitug during the 14-week induction phase. Participants were re-randomised to receive either 450 mg or 900 mg subcutaneous doses every four weeks, for up to 58 weeks of exposure.
At week 44, nearly half of patients with UC achieved clinical remission, with higher rates at the 900 mg dose. In CD, more than half of patients on the higher dose achieved endoscopic response, reinforcing Duvakitug's durable efficacy.
Safety outcomes were consistent with the induction phase, confirming Duvakitug's tolerability over extended use. These findings strengthen the rationale for ongoing Phase 3 programs in both UC and CD, which will be critical for regulatory advancement.
TEVA closed Thursday's trading at $34.33, up at 0.64%.
Genentech, a member of the Roche Group (RHHBY), announced that its lead candidate, Gazyva or obinutuzumab, met its primary endpoint, showing statistically significant and clinically meaningful results in the Phase III MAJESTY study in adults with primary membranous nephropathy.
Gazyva is a glycoengineered, anti-CD20 monoclonal antibody designed to achieve deep tissue B cell depletion.
MAJESTY is the fourth positive Phase III study of Gazyva in immune-mediated diseases, following REGENCY in lupus nephritis, ALLEGORY in systemic lupus erythematosus and INShore in idiopathic nephrotic syndrome.
Results showed that significantly more people achieved complete remission at 104 weeks with Gazyva than with tacrolimus.
The analysis of key secondary endpoints showed statistically significant and clinically meaningful benefits with Gazyva versus tacrolimus in overall remission at week 104 and complete remission at week 76.
Safety was in line with the well-characterised profile of Gazyva, and no new safety signals were identified. Data will be presented at an upcoming medical meeting and shared with health authorities, including the U.S. Food and Drug Administration and the European Medicines Agency.
RHHBY closed Thursday's trading at $59.24, down at 0.69%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020

Key Points
Sold 4,177,000 shares of KBWB; estimated transaction value approximately $330 million (based on quarterly average price).
Quarter-end position value declined by $327 million, reflecting share sale and price movement.
Represents a 2.9% change in 13F reportable assets under management (AUM).
Post-trade holding: 620 shares, valued at $52,000.
The position was previously 2.9% of the fund's AUM as of the prior quarter.
Harel Insurance Investments & Financial Services Ltd. disclosed in its Feb. 3, 2026, SEC filing that it sold 4,177,000 shares of the Invesco KBW Bank ETF (KBWB), an estimated $330 million transaction based on the quarterly average price.
What happened
According to a filing with the Securities and Exchange Commission dated Feb. 3, 2026, Harel Insurance Investments & Financial Services Ltd. reduced its stake in Invesco KBW Bank ETF by 4,177,000 shares. The estimated trade size is $330 million, calculated using the average closing price for the quarter ended Dec. 31, 2025. The value of the position declined by $326.68 million, reflecting both trading and market movement.
What else to know
The fund’s KBWB position now accounts for virtually 0% of 13F reportable AUM after this reduction.
Top holdings after the filing:
NYSE:TEVA: $1.40 billion (12.1% of AUM)
NYSEMKT:XLV: $653.9 million (5.7% of AUM)
NASDAQ:GOOGL: $506.5 million (4.3% of AUM)
NASDAQ:NVMI: $482.4 million (4.2% of AUM)
NASDAQ:SMH: $431.7 million (3.7% of AUM)
As of Feb. 2, 2026, shares were priced at $87.64, up 26.2% in the prior year with a 9.2 percentage point alpha versus the S&P 500.
Dividend yield reported at 1.94%; KBWB closed 1.35% below its 52-week high as of Feb. 3, 2026.
ETF overview
AUM
N/A
Price (as of market close 2/2/26)
$87.64
Dividend yield
1.96%
1-year total return
28.05%
ETF snapshot
Investment strategy seeks to replicate the performance of a modified market-cap-weighted index of U.S. banking institutions, focusing on large national money centers, regional banks, and thrift institutions.
The portfolio is concentrated in publicly traded U.S. banks, with at least 90% of assets allocated to securities comprising the underlying index.
The fund operates as a non-diversified ETF, offering exposure to the U.S. banking sector with a moderate dividend yield and a transparent index methodology.
Invesco KBW Bank ETF (KBWB) provides targeted exposure to the U.S. banking sector by tracking a benchmark of leading national and regional banks. The fund's strategy is designed to capture the performance of the largest and most liquid U.S. banking institutions, making it a specialized tool for investors seeking sector-specific allocation. With a sizable asset base and a disciplined, index-driven approach, KBWB offers institutional investors a liquid, cost-efficient means to access the U.S. banking industry.
What this transaction means for investors
Institutional investors are making many decisions amid changing interest rates and economic uncertainty heading into the new year. Investors are anticipating lower interest rates, which would put pressure on banks’ (KBWB) ability to generate higher net interest margin and profits.
A bank ETF like KBWB could see more modest gains in a falling rate environment. Following two rate cuts by the Federal Reserve, it makes sense to take profits as interest rates come down, especially after a strong year of gains.
Harel Insurance reduced its investment in KBWB while adding to its largest holdings that offer exposure to healthcare (TEVA and XLV) and technology (GOOGL, NVMI, and SMH), which could benefit under improving economic conditions and corporate spending on artificial intelligence (AI).
Should you buy stock in Invesco Exchange-Traded Fund Trust II - Invesco Kbw Bank ETF right now?
Before you buy stock in Invesco Exchange-Traded Fund Trust II - Invesco Kbw Bank ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Invesco Exchange-Traded Fund Trust II - Invesco Kbw Bank ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $432,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,067,820!*
Now, it’s worth noting Stock Advisor’s total average return is 894% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 5, 2026.
John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Harel Insurance Sold $330 Million of Invesco KBW Bank ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI International Developed Markets ETF (Symbol: IDEV) where we have detected an approximate $1.3 billion dollar inflow -- that's a 4.8% increase week over week in outstanding units (from 298,500,000 to 312,900,000). Among the largest underlying components of IDEV, in trading today Spotify Technology SA (Symbol: SPOT) is down about 4.2%, Sea Ltd (Symbol: SE) is off about 5.1%, and Teva Pharmaceutical Industries Ltd (Symbol: TEVA) is higher by about 3.5%. For a complete list of holdings, visit the IDEV Holdings page » The chart below shows the one year price performance of IDEV, versus its 200 day moving average:
Looking at the chart above, IDEV's low point in its 52 week range is $61.11 per share, with $87.96 as the 52 week high point — that compares with a last trade of $87.03. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Funds Holding ELAB
CHGG shares outstanding history
COSO market cap history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable ETF Inflow Detected - IDEV, SPOT, SE, TEVA

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

Teva (TEVA) Q3 2025 Earnings Call Transcript

Johnson & Johnson JNJ delivered strong fourth-quarter 2025 results, with both the top and bottom lines exceeding expectations. Total revenues rose 9.1% to $24.56 billion, while adjusted EPS of $2.46 rose 20.6% year over year.
Despite the loss of exclusivity (“LOE”) of its multi-billion-dollar product, Stelara, sales in J&J’s Innovative Medicines unit rose 10.0% year over year to $15.76 billion in the fourth quarter. Its MedTech segment also showed continued improvement, driven by strong performance in Cardiovascular, Surgery and Vision. Sales in the MedTech segment rose 7.5% to $8.8 billion in the fourth quarter.
J&J’s 2026 guidance was also above expectations. J&J said it expects sales in the range of $100.0 billion-$101.0 billion in 2026. Adjusted earnings per share are expected to be in the range of $11.43-$11.63. J&J expects accelerated growth in both the Innovative Medicine and MedTech segments in 2026.
However, a single quarter’s results are not so important for long-term investors, and the focus should rather be on the company’s strong fundamentals. Let’s understand the company’s strengths and weaknesses to better analyze how to play J&J stock in the post-earnings scenario.
JNJ’s Innovative Medicine Showing Consistent Strength
J&J’s Innovative Medicine unit is showing a growth trend. The segment’s sales rose 4.1% on an organic basis in 2025 despite Stelara LOE and the negative impact of the Part D redesign. Growth was driven by J&J’s key drugs like Darzalex, Erleada and Tremfya. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato also contributed significantly to growth.
The segment recorded three consecutive quarters of sales of more than $15 billion despite the LOE of Stelara. The segment, for the first time, generated more than $60 billion in full-year sales in 2025, with13 brands growing in double digits.
In 2026, J&J expects accelerated growth in the Innovative Medicine segment despite the Stelara LOE impact. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato, Carvykti and Erleada, as well as new launches like Rybrevant plus Lazcluze in non-small cell lung cancer and Caplyta in major depressive disorder (MDD). J&J expects a more pronounced impact from new products in 2026 than in 2025. It expects the Innovative Medicine business to grow 5% to 7% from 2025 to 2030.
J&J’s Significant Pipeline Progress in 2025
In 2025, J&J invested over $32 billion in R&D and M&A, including the acquisitions of Intra-Cellular Therapies and Halda Therapeutics.
The company rapidly advanced its pipeline in the year, attaining significant clinical and regulatory milestones that will help drive growth through the back half of the decade. In 2025, it gained approval for new products like Inlexzoh/TAR-200, a first-of-its-kind drug-releasing system, for treating high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for treating generalized myasthenia gravis. J&J believes that nipocalimab has a pipeline-in-a-product potential. Regulatory applications were recently filed for another key candidate, Icotyde/icotrokinra, for moderate-to-severe plaque psoriasis. J&J believes that Icotyde/icotrokinra has the potential to revolutionize the treatment of plaque psoriasis with a once-a-day pill.
Three of J&J’s new cancer drugs are Carvykti, a BCMA CAR-T therapy for relapsed or refractory multiple myeloma; Tecvayli, for relapsed or refractory multiple myeloma; and Talvey, a novel bispecific therapy for heavily pretreated multiple myeloma. These drugs have also begun to contribute to top-line growth. Combined, they generated $3.0 billion in sales in 2025.
J&J’s acquisition of Intra-Cellular Therapies added antidepressant drug, Caplyta, to its neuroscience portfolio, which is approved for the treatment of schizophrenia, depression in both bipolar 1 and 2, and MDD.
J&J believes 10 of its new products/pipeline candidates in the Innovative Medicine segment have the potential to deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta, Inlexzo, Rybrevant, plus Lazcluze and Icotyde.
J&J’s MedTech Segment Sales Improving
J&J’s MedTech business has improved in the past three quarters, driven by the acquired cardiovascular businesses, Abiomed and Shockwave, as well as Surgical Vision and wound closure in Surgery. Improvements in J&J’s electrophysiology business also drove the growth. MedTech sales rose 4.3% on an organic basis in 2025.
Moreover, the potential separation of its Orthopaedics franchise into a standalone orthopedics-focused company, called DePuy Synthes, should improve its MedTech unit’s growth and margins. The Orthopaedics franchise has been a slow-growth business for J&J.
In 2026, J&J expects better growth in the MedTech business than 2025 levels, driven by increased adoption of newly launched products across Cardiovascular, Surgery and Vision portfolios. Some key new product launches are VARIPULSE in Electrophysiology, ETHICON4000 in Surgery and the OASYS MAX family in Vision.
However, the company continues to face headwinds in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program, which is a government-driven cost containment effort in China. J&J expects continued impacts from VBP issues in China in 2026.
Patent Expiration of J&J’s Drug Stelara & Other Headwinds
J&J lost U.S. patent exclusivity of Stelara in 2025. Stelara was a key top-line driver for J&J, accounting for around 18% of J&J’s Innovative Medicine unit’s sales in 2024, before it lost patent exclusivity in 2025.
Several biosimilar versions of J&J’s multi-billion-dollar immunology drug, Stelara, were launched in the United States in 2025 as the drug lost patent exclusivity.
According to patent settlements and license agreements, Amgen AMGN, Teva Pharmaceutical Industries TEVA, Samsung Bioepis/Sandoz and some other companies launched Stelara biosimilars in 2025. Stelara’s LOE negatively impacted the Innovative Medicines segment’s growth by 1040 basis points in 2025. In 2026, J&J expects Stelara LOE impact to be more pronounced. In addition, J&J expects generic impact for both Simponi and Opsumit to begin in 2026 as the drugs lose patent protection.
In addition, sales are being hurt by the impact of the Medicare Part D redesign under the Inflation Reduction Act (IRA). The Part D redesign is mainly affecting sales of drugs like Stelara, Erleada and pulmonary hypertension drugs.
J&J faces more than 73,000 lawsuits for its talc-based products, primarily baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. J&J insists that its talc-based products are safe and do not cause cancer. The company permanently discontinued the sales of the talc-based Johnson’s Baby Powder.
In April 2025, a bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle its talc lawsuits after a two-week trial in Houston. J&J has gone back to the traditional tort system to fight the lawsuits individually, with its bankruptcy strategy to settle the lawsuits failing for the third time.
J&J Stock Price, Valuation and Estimates
J&J’s shares have outperformed the industry in the past year. The stock has risen 48.5% in the past year compared with a 20.0% increase of the industry. The stock has also outperformed the sector and the S&P 500 Index, as seen in the chart below.
JNJ Stock Outperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 19.36 forward earnings, higher than 18.36 for the industry. The stock is also trading above its five-year mean of 15.65.
JNJ Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has risen from $11.46 to $11.53 over the past seven days, while that for 2027 has gone up from $12.25 per share to $12.31 per share over the same timeframe. The EPS estimates have moved up in response to J&J’s optimistic 2026 financial outlook.
JNJ Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in J&J’s Stock
J&J’s biggest strength is its diversified business model, as it operates through pharmaceuticals and medical devices divisions. It has more than 275 subsidiaries and boasts 28 platforms or products with more than $1 billion in annual sales. Its diversification helps it to withstand economic cycles more effectively. It also boasts strong cash flows and has consistently increased its dividends for 63 consecutive years.
J&J outperformed financial expectations in 2025 and looks optimistic for continued strong momentum in 2026 with a target to generate around $100 billion in revenues in the year. J&J expects sales growth in both segments to be higher in 2026.
Despite headwinds like the legal battle surrounding its talc lawsuits, the Stelara patent cliff, the upcoming LOE of key drugs Opsumit and Simponi and softness in MedTech China, J&J looks quite confident that it will be able to navigate these challenges.
J&J’s price appreciation, rising estimates, consistent earnings and sales growth, important new launches and significant pipeline progress suggest one should stay invested in this Zacks Rank #3 (Hold) stock for now. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quantum Computing Stocks Set To Soar
Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.
Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.
Access the Report Free Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum Score
Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM Score
What if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +23.81% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Teva Pharmaceutical Industries Ltd. (TEVA)
<span>Headquartered in Tel Aviv, Israel, Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs (includes biosimilars and over-the-counter (“OTC”) products), as well as active pharmaceutical ingredients (APIs) in North America, Europe, Latin America, India, and Israel. Teva’s generic product portfolio includes tablets, capsules, liquids, ointments, creams, transdermal patches, injectables, and inhalants. Teva plans to separate its API unit into a standalone business unit through a sale.
TEVA is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 7.75; value investors should take notice.
For fiscal 2025, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.02 to $2.55 per share. TEVA boasts an average earnings surprise of +5.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, TEVA should be on investors' short list.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock

(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), Wednesday announced the fourth quarter financial results, reporting net profit of $480 million, or $0.41 per share, attributable to the company, compared with net loss of $217 million, or $0.19 per share, last year.
On an adjusted basis, earnings increased to $1.130 billion, or $0.96 per share, from $816 million, or $0.71 per share, in the previous year.
Analysts, on average, estimated earnings of $0.64 per share for the quarter.
Revenue went up to $4.711 billion from $4.229 billion in the prior year, mainly due to development milestone payments received in connection with the initiation of Phase 3 studies for duvakitug and from higher revenues from our key innovative products.
Looking ahead, the company sees full year 2026 revenue outlook of $16.4 - $16.8 billion and adjusted earnings of $2.57 - $2.77 per share.
On average, analysts anticipate earnings of $2.77 per share and revenue of $16.99 billion for the full year 2026.
In the pre-market hours, TEVA is trading at $32.55, up 0.08 percent on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.